Clinical Trial Update: Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of selonsertib in adults with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Selonsertib (selonsertib)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis | Phase 3 | Status: TERMINATED | Results posted: 2020-05-07